Allergy Immunotherapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Allergy Immunotherapy Market
The Allergy Immunotherapy market size was valued at USD 1.70 billion in 2023, and the market is now projected to grow from USD 1.84 billion in 2024 to USD 4.02 billion by 2032, exhibiting a CAGR of 10.3% during the forecast period of 2024-2032.
The market seen drowsy development amid the widespread owing to the decrease in persistent visits since of the execution of rigid lockdowns and stay-at-home rules. Besides, the increment within the utilization of veils and confined outdoor activities to check the transmission of COVID-19 disease had diminished the patient's introduction to allergens, hence lessening quiet numbers and eventually affecting the advertise development.
In spite of subcutaneous immunotherapy (SCIT) being the gold standard for allergy treatment with high adequacy, the market is seeing a continuous move towards sublingual tablets and drops. Benefits such as less systemic unfavorably susceptible responses and secure & simple organization of tablets compared to sensitivity shots have expanded persistent inclination for sublingual over subcutaneous items.
Allergic conditions adversely influence the quality of life of a person by impeding different physiological capacities. The rising predominance of hypersensitivities among individuals over the globe owing to expanded presentation to different allergens such as dusts, tidy vermin, molds, and others, is raising the demand for a compelling treatment regimen such as sensitivity immunotherapy (AIT). The predominance of hypersensitivities is developing exponentially in developing and Western nations, leading to a spike within the request and appropriation of immunotherapy.
Comprehensive Analysis Of Allergy Immunotherapy Market
Based on sort, the advertise is sectioned into subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (Slit). The SCIT portion overwhelmed the worldwide sensitivity immunotherapy market share in 2023 because it is the gold standard for the treatment of allergies with high viability compared to Slit therapy. On the premise of sign, the advertise is categorized into allergic rhinitis, allergic asthma, and others. The allergic rhinitis portion is expected to overwhelm the advertise amid the ponder period owing to the developing burden of allergic rhinitis cases. On the premise of dissemination channels, the market is fragmented into healing center drug stores and retail & online drug stores. The retail and online drug stores fragment overwhelmed the market share owing to the comfort and extraordinary rebates advertised and the quality client administrations given by these dispersion channels.
Europe created a revenue of USD 1.20 billion in 2023 and will overwhelm the market all through the estimate period. The rising prevalence of sensitivities within the region, and consistent endeavors by the governments and companies to create and dispatch sensitivity immunotherapy items are the key components advancing market development.
The market is semi-consolidated owing to the nearness of some players such as ALK (Denmark), Zhejiang Wolwo Bio-pharmaceutical Co., Ltd (China), Stallergenes Greer (Switzerland), HollisterStier Allergy (U.S.), Allergy Therapeutics (U.K.), HAL Allergy B.V. (Netherlands), LETIPharma (Spain), Dermapharm Holding SE (Germany). The solid initiatives by the company to strengthen its nearness exterior Europe, its vigorous item pipeline, and venture toward inquire about and advancement of subcutaneous and sublingual items for different allergens, are contributing to its income development.
Within the month of October 2023 the company ALK declared the effective completion of the stage 3 trial of Itulatek for treating tree-pollen-induced unfavorably susceptible rhinoconjunctivitis.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Growth Rate CAGR of 10.3% from 2024-2032
Unit Value (USD billion)
Segmentation By Type
Subcutaneous Immunotherapy
Sublingual Immunotherapy
By Application
Allergic Rhinitis
Allergic Asthma
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies & Online Pharmacies
By Geography
North America (By Type, By Application, By Distribution Channel, By Country)
- U.S.
- Canada
Europe (By Type, By Application, By Distribution Channel, By Country /Sub-Region)
- Germany
- France
- U.K.
- Italy
- Spain
- Netherlands
- Belgium
- Poland
- Sweden
- Norway
- Denmark
- Rest of Europe
Asia Pacific (By Type, By Application, By Distribution Channel, By Country /Sub-Region)
- China
- India
- Japan
- Australia
- South Korea
- Southeast Asia
- Rest of Asia Pacific
Latin America (By Type, By Application, By Distribution Channel, By Country /Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa (By Type, By Application, By Distribution Channel, By Country /Sub-Region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.